Background-As a substudy of the large, randomized ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) trial comparing first-and second-generation drug-eluting stents, we evaluated intimal hyperplasia (IH) and vascular changes using volumetric intravascular ultrasound analysis. Methods and Results-Complete angiographic and volumetric intravascular ultrasound data immediately after stenting and at 9-month follow-up were available in 162 patients with 183 lesions: 61 sirolimus-eluting stents (SES), 64 paclitaxel-eluting stents (PES), and 58 zotarolimus-eluting stents (ZES). External elastic membrane, stent, lumen, and peristent plaque volumes (external elastic membrane minus stent) were normalized by stent length. Percent IH volumes were calculated as [IH volume/stent volume]ϫ100, %. Reduction of minimal luminal area) was greater in PES than SES (Ϫ1.4Ϯ1.5 mm 2 versus Ϫ0.7Ϯ0.9 mm 2 , Pϭ0.003), whereas minimal luminal area change in ZES was not significantly different from SES (Ϫ1.2Ϯ1.0 mm 2 versus Ϫ0.7Ϯ0.9 mm 2 , Pϭ0.055). Percent IH volume was less in SES compared with PES (9.8Ϯ6.0% versus 17.5Ϯ11.2%, Pϭ0.002) or with ZES (9.8Ϯ6.0% versus 18.2Ϯ7.6%, Pϭ0.005). Comparing ZES versus PES, there were no significant differences in %IH volume (17.5Ϯ11.2% versus 18.2Ϯ7.6%, Pϭ0.779) or changes in normalized lumen volume (Ϫ1.2Ϯ1.3 mm 2 versus Ϫ1.1Ϯ0.8 mm 2 , Pϭ0.452). Late stent malapposition was identified in 8 (13%) SES and 2 (3%) PES but in no ZES (Pϭ0.050). Angiographic restenosis was detected in 6 lesions (3 PES and 3 ZES). Conclusions-The degree of neointimal growth in ZES was similar to that in PES but less than that in SES. ZES had no late stent malappositions. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00418067. (Circ Cardiovasc Interv. 2011;4:139-145.)
T he 2 first-generation, polymer-based, drug-eluting stents (DES) approved by the US Food and Drug Administration-sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES)-have reduced the rate of restenosis and the need for repeat revascularization. However, there are concerns about stent thrombosis and late neointimal "catch-up" related to an altered arterial healing or to an inflammatory response to the DES. [1] [2] [3] Although the second-generation zotarolimus-eluting stent (ZES) has been developed to enhance safety and offer similar or better efficacy compared with first-generation DES, there are few intravascular ultrasound (IVUS) studies demonstrating these effects. 4, 5 Clinical Perspective on p 145
The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) trial is a multicenter, prospectively randomized, "all comers" study to compare ZES versus SES and PES in 2645 patients undergoing percutaneous coronary intervention. The data showed that the use of ZES resulted in similar rates of major adverse cardiac events compared with SES, and in fewer major adverse cardiac events compared with PES during 1 year of follow-up.
As a substudy of the ZEST trial, we performed a volumetric IVUS substudy to compare intimal hyperplasia (IH), late stent malapposition (LSM), and vascular remodeling among these 3 stents.
Methods
Data were derived from the ZEST trial that was a prospective, randomized, single-blind, controlled study conducted in 19 centers between October 2006 and January 2008. The study was an "allcomers" design involving consecutive enrollment of patients with stable angina or acute coronary syndromes who had at least 1 coronary lesion (defined as a stenosis of Ͼ50%) suitable for stent implantation. Exclusion criteria were ST-elevation myocardial infarction necessitating primary percutaneous coronary intervention; severely compromised ventricular dysfunction (ejection fraction Ͻ25%) or cardiogenic shock; drug allergy; left main coronary artery disease (defined as a stenosis of Ͼ50%); in-stent restenosis of previously implanted DES; terminal illness; and participation in another coronary device study. Eligible patients were randomly assigned on a 1:1:1 basis to treatment with ZES (Endeavor; Medtronic Vascular), SES (Cypher select; Cordis, Johnson & Johnson, Miami Lakes, FL), or PES (TAXUS Liberte, Boston Scientific Corp, Natick, MA). All patients signed written informed consent. The sponsor of this study contributed to study design but had no role in data collection, monitoring, analysis, interpretation, or writing of the manuscript.
The current follow-up angiographic and IVUS analysis, which was a single-center substudy of the ZEST trial, included all patients evaluated and treated at the Asan Medical Center, Seoul, Korea, who underwent poststenting and 9-month IVUS and quantitative angiography.
All procedures were performed by standard techniques. Heparin was administered during the procedure to maintain an activated clotting time of 250 seconds or longer. The use of glycoprotein IIb/IIIa inhibitors was at the discretion of the operators. Before the procedure, all patients received at least 100 mg of aspirin and a 300 to 600 mg loading dose of clopidogrel; this was followed by aspirin (100 to 200 mg/d) indefinitely and clopidogrel (75 mg/d) for at least 12 months.
Angiographic Analysis
All eligible patients were requested to return for angiographic follow-up between 8 to 10 months after the procedure. Quantitative angiographic measurements were done by standard techniques with automated edge-detection algorithms (CASS-5, Pie-Medical, Maastricht, the Netherlands) in the angiographic analysis center of the CardioVascular Research Foundation, Seoul, Korea. 6, 7 Angiographic image acquisition was performed at target sites using 2 or more angiographic projections of the stenosis at baseline, after stenting, and at 9 months. Angiographic restenosis was defined as a diameter stenosis Ͼ50% at follow-up angiography.
IVUS Imaging and Analysis
IVUS imaging was performed after intracoronary administration of 0.2 mg nitroglycerin, using a motorized transducer pullback (0.5 mm/s) and a commercial scanner (Boston Scientific/SCIMED, Minneapolis, MN) consisting of a rotating 40-MHz transducer within a 3.2F imaging sheath. The decision to perform IVUS and the decision to use IVUS information to guide the percutaneous coronary intervention procedure was at the operator's discretion.
All IVUS data were assessed off-line by experienced accessors unaware of the allocated stent type or clinical information in a core laboratory at the Asan Medical Center. Quantitative volumetric IVUS analysis was performed as previously described. 8, 9 Using computerized plannimetry (EchoPlaque 2.7, Indec Systems, Mountain View, CA), stent and reference segments were assessed every 1 mm. Reference segment external elastic membrane (EEM), lumen, and plaqueϩmedia (EEM minus lumen) areas were measured over a 5-mm length adjacent to each stent edge and averaged. In-stent measurements were also obtained every 1 mm and included EEM, stent, intrastent lumen, peristent plaqueϩmedia (EEM minus stent), and IH (stent minus intrastent lumen) areas and volumes. Percent IH was defined as IH divided by stent. All volumes were calculated using the Simpson rule and then normalized by stent length (normalized volume).
Using segmental analysis with head-to-head comparison between poststenting and follow-up images, vascular remodeling was assessed by the serial changes in %EEM area ([follow-up EEM areaϪpoststenting EEM area]/poststenting EEM area)ϫ100. Focal expansive remodeling was defined as a Ͼ10% increase in EEM area over at least 3 consecutive 1-mm segments, and focal constrictive remodeling was defined as a Ͼ10% decrease in EEM area over at least 3 consecutive 1-mm segments. Diffuse expansive or constrictive remodeling was defined as Ͼ10% increase or decrease in normalized vessel volume of the entire in-stent region compared with poststenting normalized vessel volume. Lesions were excluded if they showed nonuniform rotational distortion, a difference in total stent length Ͼ2 mm between poststenting and follow-up, or mismatched segments.
LSM was defined as separation of at least 1 stent strut away from the intimal surface of the arterial wall that was not overlapping a side branch, was not present immediately after stent implantation, and had evidence of blood speckling behind the strut. 10 
Statistical Analysis
All statistical analyses were performed using SAS release 9.1 (SAS Institute Inc, Cary, NC) or SPSS (version 10.0, SPSS Inc, Chicago, IL). Data were analyzed on a per-patient and per-lesion basis for the corresponding calculations. All values are expressed as meanϮstandard deviation (continuous variables) or as counts and percentages (categorical variables). For the per-patient data, continuous variables were compared by use of 1-way ANOVA or nonparametric Kruskal-Wallis test; categorical variables were compared with the 2 statistics or Fisher exact test. For the per-lesion data, linear mixed models that accounted for the clustering between lesions in same subject were created. All probability values were 2-sided, and probability values Ͻ0.05 were considered to indicate statistical significance.
In post hoc analysis, all IVUS parameters were compared among the 3 DES types; Bonferroni corrections were made for multiple comparisons of continuous variables. All probability values were 2-sided, and probability values after Bonferroni correction Ͻ0.05 were considered to indicate statistical significance.
Results
Complete angiographic and volumetric IVUS data immediately after stenting and at 9-month follow-up were available in 162 patients with 183 lesions: 61 SES, 64 PES, and 58 ZES. Twenty-one patients had 2 lesions. Baseline clinical and angiographic characteristics were similar among the groups (Table 1) . Follow-up angiography showed that late luminal loss at 9 months in SES was less than in PES or ZES, but late luminal loss at 9 months in ZES was not significantly different from PES ( Table 2) . Angiographic restenosis was detected in 6 lesions (3 PES and 3 ZES). Clinical characteristics and angiographic findings in the IVUS substudy patients were similar to the overall ZEST study cohort (data not shown).
IVUS Analysis
At baseline, ZES had a smaller poststenting minimal lumen area (MLA) and a smaller poststenting normalized lumen volume compared with PES. Volumetric IVUS measurements after stenting and at 9-month follow-up are summarized in Table 3 . The 9-month reduction in IVUS MLA was more remarkable in PES than SES (Ϫ1.4Ϯ1.5 mm 2 versus Ϫ0.7Ϯ0.9 mm 2 , Pϭ0.003), whereas the 9-month reduction in MLA in ZES was not significantly different from SES (Ϫ1.2Ϯ1.0 mm 2 versus Ϫ0.7Ϯ0.9 mm 2 , Pϭ0.055, Table 4 ). The changes in MLA were similar between ZES and PES (Ϫ1.2Ϯ1.0 mm 2 versus 1.4Ϯ1.5 mm 2 , Pϭ0.24).
The %IH volume at 9 months was less in SES compared with PES (9.8Ϯ6.0% versus 17.5Ϯ11.2%, Pϭ0.002) or with ZES (9.8Ϯ6.0% versus 18.2Ϯ7.6%, Pϭ0.005). Moreover, the reduction of normalized luminal volume in SES was less than in ZES (Ϫ0.5Ϯ0.7 mm 2 versus Ϫ1.1Ϯ0.8 mm 2 , Pϭ0.007) or PES (Ϫ0.5Ϯ0.7 mm 2 versus Ϫ1.2Ϯ1.3 mm 2 PϽ0.001). However, comparing PES to ZES, there was no significant difference in %IH volumes at 9 months (17.5Ϯ11.2% versus 18.2Ϯ7.6%, Pϭ0.78) or changes in normalized lumen volume (Ϫ1.2Ϯ1.3 mm 2 versus Ϫ1.1Ϯ0.8 mm 2 , Pϭ0.45).
Vascular Remodeling and LSM
There was no significant difference among the 3 DES groups with regard to changes in normalized vessel, stent, or peristent plaque volumes. Diffuse expansive remodeling was detected in 14 (23%) SES-treated, 13 (20%) PES-treated, and 9 (16%) ZES-treated lesions (Pϭ0.58). Diffuse constrictive remodeling was seen in 3 (5%) SES-treated, 4 (6%) PEStreated, and 2 (3%) ZES-treated lesions (Pϭ0.77). Additionally, focal expansive remodeling was identified in 33 (54%) SES-treated, 32 (50%) PES-treated, and 23 (40%) ZEStreated lesions (Pϭ0.27), whereas 12 (20%) SES-treated, 9 (14%) PES-treated, and 14 (24%) ZES-treated lesions included segments with focal constrictive remodeling (Pϭ0.37). Severe focal expansive remodeling (Ͼ20% increase in EEM area) was observed in 22 (40%) SES-treated, 18 (30%) PES-treated, and 13 (25%) ZES lesions (Pϭ0.08). Overall, 10 (5.5%) lesions revealed both expansive and constrictive remodeling in the same in-stent segment.
LSM was identified in 8 (13%) SES-treated and 2 (3%) PES-treated but in no ZES-treated lesions (Pϭ0.050, which was calculated by logistic regression with generalized estimation equation).
In the proximal and distal reference segments, there were no significant changes in EEM, lumen, or P&M areas in the 3 DES groups between stent implantation and 9 months.
Discussion
The mean %IH volume of 18.2% in ZES in the current study was in accordance with previous randomized, controlled trials (17.4% in ENDEAVOR II and 16.1% in the IVUS cohort of ENDEAVOR III). [11] [12] [13] [14] Despite much greater %IH volume in ZES compared with SES in these and in the current study, the loss of MLA in ZES was not significantly different from that in SES. Because of the longitudinal pattern of neointimal distribution over the stented length, focal neointimal accumulation will result in a smaller %IH volume than diffuse neointimal distribution. Most neointimal proliferation seen in SES has been reported to be focal, whereas a previous study reported that ZES evenly inhibited neointimal growth resulting in more diffuse neointimal hyperplasia. 4 The current findings are more notable because, unlike ENDEAVOR II or ENDEAVOR III, our study was an attempt to reflect routine clinical practice and had an "all-comers" design involving the consecutive enrollment of eligible patients with either stable angina or acute coronary syndrome who had at least 1 coronary lesion with no limitation on the number of lesions or vessels or on the lengths of the lesions.
In the present study, %IH volumes and the reduction in normalized lumen volume in ZES are similar to PES. Because %IH volume presumably represents the overall inhibitory effect of each device on neointimal growth, these findings indicate that the efficacy of ZES is comparable to PES. In most patients treated with PES, neointimal accumulation is below the threshold of physiological significance. 15 However, the permissible range of neointimal growth still remains unclear.
A recent report demonstrates that the lack of intimal hyperplasia is related to late DES thrombosis as the result of impaired reendothelialization and delayed arterial healing. 16 ENDEAVOR II and III demonstrate an improved safety profile in ZES that was attributed to the relatively complete and uniform neointima that, nevertheless, is associated with a clinically acceptable late lumen loss. 4, 5 Although excessive neointimal growth results in target lesion revascularization, the coverage of stent struts with a small amount of neointima as seen in ZES may provide a potential advantage for device safety. 11, 12 
Late Stent Malapposition
Concerns have been raised about late acquired stent malapposition and long-term clinical events such as late stent thrombosis. 17, 18 The incidence of late acquired stent malapposition has been reported from 3% to 13% in SES and from 2% to 8% in PES 19,20 -22 ; our data showed a similar incidence. No LSM was detected in ZES-treated lesions, also consistent with previous data; there was no late-acquired incomplete stent appositions in patients treated with ZES in ENDEAVOR II and only 1 such case in ENDEAVOR III. 11, 12 Recent studies have suggested that LSM may result from pathological positive vessel remodeling at the site there the strut becomes separated from the vessel. 23, 24 Previous studies showed no unfavorable vascular responses with ZES compared with the control bare metal stent, 4 and no significant serial changes in mean vessel area were found in ZES-treated lesions. 11, 12 Similarly, our data revealed no significant differences in changes in normalized EEM volumes or in the incidence of diffuse expansive remodeling among the three DES groups. However, there was a trend toward a lower incidence of severe focal expansive remodeling in ZES compared with SES (25% versus 40%, Pϭ0.080). We need further studies to confirm if these IVUS findings including a lower incidence of LSM, greater neointimal coverage of stent struts, and smaller and less frequent expansive remodeling may enhance the safety of ZES compared with SES and PES.
Limitations
We did not evaluate neointimal coverage over the stent surface. The endothelial layer is below the axial resolution of IVUS. Furthermore, to validate the clinical utility of the ZES and to find the relationship between the neointimal coverage and clinical outcomes, additional long-term follow-up investigations in larger patient numbers are needed. The current substudy was single-center based and could not include all patients enrolled in ZEST trial because of early restenosis, repeat revascularization, patient refusal for IVUS examination, or technical difficulty in the test. Because the substudy cohort could not completely reflect the characteristics of overall population in the real world, these pitfalls and potential for selection bias may limit the external validity of the findings and should be thoroughly considered before extending these observations to the general cohort of patients undergoing routine DES implantation.
Conclusions
Although ZES is less effective in inhibiting intimal hyperplasia than SES, ZES showed efficacy comparable to PES. The implication of lack of LSM on the safety of ZES needs further study with long-term follow-up.
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